Janus kinase 1/2 inhibition with Baricitinib for treatment of anti-signal recognition particle necrotizing autoimmune myositis: a case report
Article Sidebar
Main Article Content
Abstract
Following recent success in dermatomyositis treatments, Baricitinib, a selective Janus Kinase 1/2 (JAK1/JAK2) inhibitor, has been the subject of speculation as a potential new remedy for IIM. In this case report, our patient was presented with a typical clinical symptoms of necrotizing autoimmune myositis (NAM), a subset under an umbrella of idiopathic inflammatory myopathy (IIM), and was treated according to European neuromuscular center’s (ENMC) protocol but to no avail. It was then decided that Baricitinib would be administrated as a rescue treatment. In that order, this has become the very first documented use of Baricitinib against the IIM other than dermatomyositis. Despite the unfortunate adverse events of disseminated tuberculosis, Baricitinib has indeed shown a positive outcome for the patient, suggesting a possibility for future developments and treatments of NAM.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Albrecht K, Huscher D, Callhoff J, et al. Trends in idiopathic inflammatory myopathies: cross-sectional data from the German National Database. Rheumatol Int 2020;40(10):1639-47. doi: 10.1007/s00296-020-04634-0
Ladislau L, Suárez-Calvet X, Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain 2018;141(6):1609-1621. doi:10.1093/brain/awy105
Papadopoulou C, Hong Y, Omoyinmi E, et al. Janus kinase 1/2 inhibition with Baricitinib in the treatment of juvenile dermatomyositis. Brain 2019;142(3):e8-e8. doi:10.1093/ brain/awz005
Glaubitz S, Zeng R, Schmidt J. New insights into the treatment of myositis. T h e r A d v M u s c u l o s k e l e t D i s 2020;12:1759720X1988649. doi:10.1177/1759720x19886494
Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop: Clinico-sero-pathological classifica tion of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 2018;28(1):87-99. doi:10.1016/j.nmd.2017.09.016
Allenbach Y, Benveniste O, Stenzel W, et al. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol 2020;16(12):689–701. doi:10.1038/s41584- 020-00515-9
Selvaraj V, Finn A, Lal A, et al. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials. EClinicalMedicine 2022;49:101489. doi: 10.1016/j.eclinm.2022.101489. 8. Winthrop KL, Harigai M, Genovese MC, et al. Infections in Baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis 2020;79(10):1290-7. doi: 10.1136/ annrheumdis-2019-216852.
Smolen J, Genovese M, Takeuchi T, et al. THU0166 Safety profile of Baricitinib in patients with active RA: An integrated analysis. Ann Rheum Dis 2016;75:243-4.